The addition of the OXPHOS inhibitor, IACS-010759, to CDK4/6 plus MEK inhibitors decreased cell growth and enhanced apoptosis, suggesting that direct OXPHOS inhibition could be an approach to optimize targeted therapy treatment in uveal melanoma [217]. The gene discussed is MAP2K7; the disease is uveal melanoma.